Table 1:
Baseline characteristics (N = 819).
| Characteristics | Values |
|---|---|
| Age (years), median (IQR) | 63 (56–70.7) |
| Sex, % | |
| Female | 45.8 |
| Male | 54.2 |
| Ischaemic cardiopathy, % | 19.2 |
| Heart failure, % | 9.2 |
| Stroke, % | 6.6 |
| Peripheric arteriopathy, % | 8.4 |
| Diabetic kidney disease, % | 25.4 |
| Diabetic retinopathy, % | 13.8 |
| Diabetic polyneuropathy, % | 6.7 |
| GLP-1RAs, % | 14.2 |
| Insulin, % | 27.9 |
| SGLT2 inhibitor, % | 57.1 |
| Metformin, % | 79.8 |
| Statin, % | 68.5 |
| Change from DPP-4 inhibitor, % | 33.2 |
| Antihypertensive drug, % | 67.3 |
| ACE inhibitors/ARBs, % | 57.9 |
| Semaglutide starting dose (mg), % | |
| 3 | 90.9 |
| 7 | 4.5 |
| 14 | 4.6 |
| HbA1c (%), median (IQR) | 7.9 (6.9–8.8) |
| ≥8, % | 45.4 |
| ≥9, % | 21.2 |
| eGFR (ml/min/1.73 m2), median (IQR) | 88.1 (67.6–90.0) |
| G1, % | 46.7 |
| G2, % | 34.3 |
| G3, % | 17 |
| G4, % | 2 |
| CKD, % | 47.2 |
| LDL (mg/dl), median (IQR) | 87 (65–111) |
| Triglycerides (mg/dl), median (IQR) | 162 (114–233) |
| UACR (mg/g), median (IQR) | 12 (4–45) |
| A1: <30 mg/g | 66.43 |
| A2: 30–299 mg/g | 28.31 |
| A3: ≥300 mg/g | 5.17 |
| Platelets (/μl), median (IQR) | 244 (195–280) |
| AST (U/l), median (IQR) | 21 (17–31) |
| ALT (U/l), median (IQR) | 23 (16.75–37) |
| FIB-4, median (IQR) | 1.21 (0.9–1.7) |
| At risk of liver fibrosis adjusted by age, % | 30.1 |
| FIB-4 ≥2.0 and age >65 years | 10.6 |
| FIB-4 ≥1.3 and age ≤65 years | 19.5 |
| Height (m), median (IQR) | 1.65 (1.58–1.72) |
| Weight (kg), median (IQR) | 94 (84–107.7) |
| BMI (kg/m2), median (IQR) | 33.8 (31.2–38.7) |
| <30, % | 7.8 |
| 30–35, % | 50.1 |
| 35–40, % | 21.7 |
| >40, % | 20.4 |
| Systolic blood pressure (mmHg), median (IQR) | 137 (125.8–148) |
| Diastolic blood pressure (mmHg), median (IQR) | 81 (74–90) |
DPP-4: dipeptidyl peptidase-4; ARB: angiotensin receptor blocker; ACE: angiotensin-converting enzyme.